Mostrar el registro sencillo del ítem
Retreatment with radiotherapy for symptomatic bone, brain or visceral metastases
dc.contributor.author | R Hernanz 1, A Montero, E Fernandez-Lizarbe, A Polo, A Ramos | |
dc.date.accessioned | 2024-01-18T08:56:41Z | |
dc.date.available | 2024-01-18T08:56:41Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Clin Transl Oncol . 2013 Jan;15(1):72-8. doi: 10.1007/s12094-012-0895-y. Epub 2012 Jul 20. | es |
dc.identifier.uri | http://hdl.handle.net/20.500.12020/1044 | |
dc.description.abstract | Background: The need for reirradiation in the metastatic disease appears when other modalities of treatment lose their efficacy. The aim of reirradiation in the metastatic disease is mainly palliative to control a particular symptom. However, this theoretical benefit must be confronted against the risk of an undesirable toxicity. Materials and methods: Experience with reirradiation for symptomatic bone, brain or visceral metastases are reviewed. Twenty-two patients were found to have a second palliative radiotherapy on the same location. Locatión of metastases were visceral in 5 (23 %) patients, brain in 4 (18 %) patients, spine in 1 (4.5 %) patient and bone metastasis other than spine in 12 (54.5 %) patients. Median dose delivered in the first treatment was 30 Gy (range 20-30 Gy) and 20 Gy for the second treatment (range 6-32.4 Gy). Results: A good symptomatic response after first irradiation (complete response or disappearance of >50 % of symptoms) was reached in 21 (95.5 %) of the 22 patients analyzed. After second irradiation, 82 % (18 patients) achieved a good response, 3 (14 %) patients had a moderate response (relief of symptoms <50 %) whereas no response was observed in 1 (4 %) patient. Acute toxicity was limited to grade 1-2 proctitis in 2 and 3 patients after the first and second irradiation, respectively. No cases of late toxicity after the first or second irradiation were recorded. Conclusion: A second treatment with palliative radiotherapy is feasible and well tolerated and offers the possibility of symptomatic relief in a high percentage of patients with symptomatic metastases. | es |
dc.language.iso | en | es |
dc.title | Retreatment with radiotherapy for symptomatic bone, brain or visceral metastases | es |
dc.type | article | es |
dc.identifier.doi | 10.1007/s12094-012-0895-y | |
dc.journal.title | Clinical and Translational Oncology | es |
dc.page.initial | 72 | es |
dc.page.final | 78 | es |
dc.rights.accessRights | openAccess | es |
dc.subject.area | Ciencias Biomédicas | es |